Adrian Shields
Overview
Explore the profile of Adrian Shields including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chadda K, Roberts S, Lugg S, Faniyi A, Faustini S, Webster C, et al.
Front Med (Lausanne)
. 2024 Dec;
11:1494129.
PMID: 39655234
Objectives: Vitamin D has a role in the innate immunity against pathogens and is also involved in mechanisms for reducing inflammation. VD deficiency (VDD) may increase COVID-19 infection susceptibility, however...
2.
Faustini S, Hodson J, Birtwistle J, Whitelegg A, Masuka S, Singo M, et al.
J Infect
. 2024 Sep;
89(5):106282.
PMID: 39326516
Background: Immunisation is recommended internationally to protect against pneumococcal infections in HIV-infected adults. However, vaccination schedule designs are mostly based on studies of initial rather than long-term antibody responses. This...
3.
Fink D, Idilli O, Shields A, Richter A, Burns S
J Clin Immunol
. 2024 Jul;
44(7):161.
PMID: 38990439
No abstract available.
4.
Ho A, Galgut O, Faustini S, Peters N, Shields A, Klenerman P, et al.
Lancet
. 2024 Jun;
404(10447):23-24.
PMID: 38944048
No abstract available.
5.
Standing J, Buggiotti L, Guerra-Assuncao J, Woodall M, Ellis S, Agyeman A, et al.
Nat Commun
. 2024 Feb;
15(1):1652.
PMID: 38396069
Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n ...
6.
Griffiths K, Mellado M, Chung R, Lally J, McQueen G, Sendt K, et al.
Brain Behav Immun
. 2023 Oct;
115:223-228.
PMID: 37832895
Background And Hypothesis: Use of clozapine in treatment-resistant schizophrenia is often limited due to risk of adverse effects. Cross-sectional associations between clozapine treatment and low immunoglobulin levels have been reported,...
7.
Jones R, Morales-Munoz I, Shields A, Blackman G, Legge S, Pritchard M, et al.
Brain Behav Immun
. 2023 Jul;
113:267-274.
PMID: 37494985
Background: Clozapine has unique effectiveness in treatment-resistant schizophrenia and is known to cause immunological side-effects. A transient spike in neutrophils commonly occurs in the first weeks of clozapine therapy. There...
8.
Moore S, Kronsteiner B, Longet S, Adele S, Deeks A, Liu C, et al.
Med
. 2023 Mar;
4(3):191-215.e9.
PMID: 36863347
Background: Both infection and vaccination, alone or in combination, generate antibody and T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the maintenance of such responses-and hence...
9.
Faustini S, Shields A, Banham G, Wall N, Al-Taei S, Tanner C, et al.
J Infect
. 2022 Jan;
84(4):579-613.
PMID: 35016901
No abstract available.
10.
Brown L, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, et al.
J Allergy Clin Immunol
. 2021 Nov;
149(2):557-561.e1.
PMID: 34780850
Background: Patients with some types of immunodeficiency can experience chronic or relapsing infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This leads to morbidity and mortality, infection control challenges, and...